CogniCann Phase II clinical trial
The Phase II clinical trial at the University of Notre Dame in Perth, Western Australia has been designed to evaluate the potential behavioural benefits of CogniCann on patients with dementia and Alzheimer’s disease.
The trial will enroll 50 patients and is expected to last until Q4 2021.
